PD-128,907 is a drug used in scientific research which acts as a potent and selective agonist for the dopamineD2 and D3receptors.[1] It is used for studying the role of these receptors in the brain, in roles such as inhibitory autoreceptors that act to limit further dopamine release,[2] as well as release of other neurotransmitters.[3] In animal studies, it has been shown to reduce toxicity from cocaine overdose.[4][5]
^Witkin JM, Dijkstra D, Levant B, Akunne HC, Zapata A, Peters S, et al. (March 2004). "Protection against cocaine toxicity in mice by the dopamine D3/D2 agonist R-(+)-trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol [(+)-PD 128,907]". The Journal of Pharmacology and Experimental Therapeutics. 308 (3): 957–64. doi:10.1124/jpet.103.059980. PMID14711932.
^Witkin JM, Levant B, Zapata A, Kaminski R, Gasior M (September 2008). "The dopamine D3/D2 agonist (+)-PD-128,907 [(R-(+)-trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol)] protects against acute and cocaine-kindled seizures in mice: further evidence for the involvement of D3 receptors". The Journal of Pharmacology and Experimental Therapeutics. 326 (3): 930–8. doi:10.1124/jpet.108.139212. PMID18566292.